Refine by MP, party, committee, province, or result type.
Health committee It's Lexchin, like you're going to have in two days.
June 10th, 2014Committee meeting
Dr. Joel Lexchin
Health committee I want to thank the standing committee for the opportunity to appear today. I teach health policy at York University and work as an emergency physician at the University Health Network in Toronto. I've been analyzing, talking about, and writing about pharmaceutical policy for ov
June 10th, 2014Committee meeting
Dr. Joel Lexchin
Health committee I think you might have confused what I was recommending. I'm recommending that the monitoring should be a Health Canada function. The crown corporation would be charged with manufacturing some of these products. It wouldn't guarantee continuous supply. If you have a shortage of
April 3rd, 2012Committee meeting
Dr. Joel Lexchin
Health committee Actually, we were discussing this yesterday at the pharmacy and therapeutics committee meeting of the University Health Network. They try to plan in advance for what they know about shortages coming down the pipeline. If they have anything less than a one-month supply of produc
April 3rd, 2012Committee meeting
Dr. Joel Lexchin
Health committee Okay. Connaught Labs—my history may be a little rusty—grew out of the University of Toronto after they discovered insulin, but it was taken over in the late 1970s, I think, by something called the Canada Development Corporation. It wasn't a federal department, but it was federall
April 3rd, 2012Committee meeting
Dr. Joel Lexchin
Health committee No—
April 3rd, 2012Committee meeting
Dr. Joel Lexchin
Health committee No; it was, in fact, owned by the Canada Development Corporation in the mid-1980s, but we can—
April 3rd, 2012Committee meeting
Dr. Joel Lexchin
Health committee Thank you very much, Madam Chair, for the invitation to appear here. I have a couple of roles. First of all, I work as an emergency physician in downtown Toronto, and secondly, I teach health policy at York University. Moreover, I've been studying pharmaceutical policy issues fo
April 3rd, 2012Committee meeting
Dr. Joel Lexchin